Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Менопаузальная гормональная терапия и негинекологический рак (часть II)*
Якушевская О.В., Юренева С.В., Протасова А.Э. и др. Менопаузальная гормональная терапия и негинекологический рак (часть II). Гинекология. 2019; 21 (1): 86–90.
DOI: 10.26442/20795696.2019.1.190234
DOI: 10.26442/20795696.2019.1.190234
________________________________________________
Iakushevskaia O.V., Iureneva S.V., Protasova A.E. et al. Menopausal hormone therapy and non-gynecologic cancer (part II). Gynecology. 2019; 21 (1): 86–90.
DOI: 10.26442/20795696.2019.1.190234
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Цель. Провести системный анализ имеющихся результатов исследований, посвященных возможности использования менопаузальной гормональной терапии (МГТ) у пациенток, благополучно завершивших лечение злокачественных новообразований разной локализации.
Материалы и методы. В обзор включены данные зарубежных статей, опубликованных в PubMed и Medline, и отечественные работы, помещенные на elibrary.ru за последние 20 лет.
Результаты. Полученные результаты позволяют расширить диапазон назначения МГТ у пациенток, имевших злокачественные новообразования различных органов в анамнезе. Данная работа является очередной среди немногочисленных попыток клиницистов обосновать использование МГТ как один из инструментов пока еще несовершенной реабилитации онкологических больных.
Заключение. Пациентки, успешно завершившие лечение злокачественных новообразований любой локализации, требуют создания особых условий реабилитации с целью сохранения здоровья и качества жизни. Обоснованное назначение МГТ у таких пациенток позволит избежать осложнений, обусловленных дефицитом эстрогенов после хирургического, лучевого с или без системного (цитостатического) методов лечения.
Ключевые слова: менопаузальная гормональная терапия, рак легких, рак щитовидной железы, меланома, опухоли головного мозга, рак почки, рак поджелудочной железы, рак крови, рак мочевого пузыря, гемобластозы, лимфопролиферативные заболевания.
Материалы и методы. В обзор включены данные зарубежных статей, опубликованных в PubMed и Medline, и отечественные работы, помещенные на elibrary.ru за последние 20 лет.
Результаты. Полученные результаты позволяют расширить диапазон назначения МГТ у пациенток, имевших злокачественные новообразования различных органов в анамнезе. Данная работа является очередной среди немногочисленных попыток клиницистов обосновать использование МГТ как один из инструментов пока еще несовершенной реабилитации онкологических больных.
Заключение. Пациентки, успешно завершившие лечение злокачественных новообразований любой локализации, требуют создания особых условий реабилитации с целью сохранения здоровья и качества жизни. Обоснованное назначение МГТ у таких пациенток позволит избежать осложнений, обусловленных дефицитом эстрогенов после хирургического, лучевого с или без системного (цитостатического) методов лечения.
Ключевые слова: менопаузальная гормональная терапия, рак легких, рак щитовидной железы, меланома, опухоли головного мозга, рак почки, рак поджелудочной железы, рак крови, рак мочевого пузыря, гемобластозы, лимфопролиферативные заболевания.
________________________________________________
Aim. To carry out a systematic analysis of available researches data on a possibility of using menopausal hormone therapy (MHT) in patients who successfully completed a treatment for malignant neoplasms of different localization.
Materials and methods. The review includes data of foreign articles published in PubMed and Medline and domestic articles published in Elibrary.ru over the past 20 years.
Results. The data obtained allow us to extend indications range for MHT in patients with history of malignant neoplasms in different organs. This study is one of the few attempts of clinicians to justify the use of MHT as one of the tools for the still imperfect rehabilitation of cancer patients.
Conclusion. Patients who successfully completed a treatment for malignant tumors of any localization require special conditions of rehabilitation in order to keep their health and quality of life. A reasonable MHT use in these patients will allow to avoid complications caused by estrogen deficiency followed surgery, radiation with or without systemic (cytostatic) treatment methods.
Key words: menopausal hormone therapy, lung cancer, thyroid cancer, melanoma, brain tumors, kidney cancer, pancreatic cancer, blood cancer, bladder cancer, hemoblastosis, lymphoproliferative diseases.
Полный текст
Список литературы
1. Miki Y, Abe K, Suzuki S et al. Suppression of estrogen actions in human lung cancer. Mol Cell Endocrinol 2011; 340 (2): 168–74.
2. Hsu LH, Chu NM, Kao SH. Estrogen, Estrogen Receptor and Lung Cancer. Int J Mol Sci 2017; 18 (8): 1713.
3. Chlebowski RT, Anderson GL, Manson JE et al. Lung cancer among postmenopausal women treated with estrogen alone in the women’s health initiative randomized trial. J Natl Cancer Inst 2010; 102 (18): 1413–21.
4. Clague J, Reynolds P, Henderson KD et al. Menopausal hormone therapy and lung cancer-specific mortality following diagnosis: the California teachers study. PLoS One 2014; 9 (7): e103735.
5. Ganti AK, Sahmoun AE, Panwalkar AW et al. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 2016; 24 (1): 59–63.
6. Hammar M, Christau S, Nathorst-Boos J et al. A double-blind randomized trial comparing the effects of tibolone and continuous combined HRT in postmenopausal women with menopausal symptoms. Br J Obstet Gynecol 1998; 105: 904–11.
7. Vini L, Hyer S, Pratt B, Harmer C. Management of differentiated thyroid cancer diagnosed during pregnancy. Eur J Endocrinol 1999; 140: 404–6.
8. Moleti M, Sturniolo G, Di Mauro M et al. Female Reproductive Factors and Differentiated Thyroid Cancer. Front Endocrinol (Lausanne) 2017; 8: 111.
9. Truong T, Orsi L, Dubourdieu D et al. Role of goiter and of menstrual and reproductive factors in thyroid cancer: a population- based case-control study in New Caledonia (South Pacific), a very high incidence area. Am J Epidemiol 2005; 161 (11): 1056–65.
10. Sturniolo G, Zafon C, Moleti M et al. Immunohistochemical Expression of Estrogen Receptor-a and Progesterone Receptor in Patients with Papillary Thyroid Cancer. Eur Thyroid J 2016; 5 (4): 224–30.
11. Yi JW, Kim SJ, Kim JK et al. Upregulation of the ESR1 Gene and ESR Ratio (ESR1/ESR2) is Associated with a Worse Prognosis in Papillary Thyroid Carcinoma: The Impact of the Estrogen Receptor a/b Expression on Clinical Outcomes in Papillary Thyroid Carcinoma Patients. Ann Surg Oncol 2017; 24 (12): 3754–62.
12. Zamora-Ros R, Rinaldi S, Biessy C et al. Reproductive and menstrual factors and risk of differentiated thyroid. carcinoma: the EPIC study. Int J Cancer 2015; 136: 1218–27. DOI: 10.1002/ijc.29067
13. Jastrzebska H, Gietka-Czernel M, Zgliczyński S. Hormonal replacement therapy in women after surgery for thyroid cancer treated with suppressive doses of L-thyroxine. Wiad Lek 2001; 54 (Suppl. 1): 383–8.
14. De Giorgi V, Gori A, Savarese I et al. Role of BMI and hormone therapy in melanoma risk: a case–control study. J Cancer Res Clin Oncol 2017; 143 (7): 1191–7.
15. Botteri E, Støer NC, Sakshaug S et al. Menopausal hormone therapy and risk of melanoma: Do estrogens and progestins have a different role? Int J Cancer 2017; 141 (9): 1763–70.
16. Marzagalli M, Marelli MM, Casati L et al. Estrogen Receptor b in Melanoma: From Molecular Insights to Potential Clinical Utility. Front Endocrinol (Lausanne) 2016; 7: 140.
17. Marzagalli M, Casati L, Moretti RM et al. Estrogen receptor beta agonists differentially affect the growth of human melanoma cell lines. PLoS One 2015; 10 (7): e0134396.
18. De Giorgi V, Gori A, Gandini S et al. Oestrogen receptor beta and melanoma: a comparative study. Br J Dermatol 2013; 168 (3): 513–9.
19. MacKie RM, Bray CA. Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma. Br J Cancer 2004; 90 (4): 770–2.
20. Black PM. Hormones, radiosurgery and virtual reality: new aspects of meningiomamanagement. Can J Neurol Sci 1997; 24 (4): 302–6.
21. Carroll RS, Brown M, Zhang J et al. Expression of a subset of steroid receptor cofactors is associated with progesterone receptor expression in meningiomas. Clin Cancer Res 2000; 6: 3570–5.
22. Hsu DW, Efird JT, Hedley-Whyte ET. Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 1997; 86 (1): 113–20.
23. Hilbig A, Barbosa-Coutinho LM. Meningiomas and hormonal receptors. Immunohistochemical study in typical and nontypical tumors. Arq Neuropsiquiatr 1998; 56 (2): 193–9.
24. O'Shea T, Crowley RK, Farrell M et al. Growth of a progesterone receptor-positive meningioma in a female patient with congenital adrenal hyperplasia. Endocrinol Diabetes Metab Case Rep 2016. pii: 16-0054.
25. Pines A. Hormon therapy and brain tumors. Climacteric 2011; 14 (2): 215–6.
26. Benson VS, Kirichek O, Beral V, Green J. Menopausal hormone therapy and central nervous system tumor risk: large UK prospective study and meta-analysis. Int J Cancer 2015; 136 (10): 2369–77.
27. Deli T, Orosz M, Jakab A. Hormone Replacement Therapy in Cancer Survivors – Review of the Literature. Pathol Oncol Res 2019. https:.doi.org/10.1007/s12253-018-00569-x
28. Christin-Maître S, Delemer B, Touraine P, Young J. Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy. Ann Endocrinol (Paris) 2007; 68 (2–3): 106–12.
29. Karami S, Daugherty SE, Schonfeld SJ et al. Reproductive factors and kidney cancer risk in 2 US cohort studies, 1993–2010. Am J Epidemiol 2013; 177 (12): 1368–77.
30. Zucchetto A, Talamini R, Dal Maso L et al. Reproductive, menstrual, and other hormone-related factors and risk of renal cell cancer. Int J Cancer 2008; 123 (9): 2213–6.
31. Molokwu JC, Prizment AE, Folsom AR. Reproductive characteristics and risk of kidney cancer: IowaWomen’s. Maturitas 2007; 58 (2): 156–63.
32. Basakci A, Kirkali Z, Tuzel E et al. Prognostic significance of estrogen receptor expression in superficial transitional cell carcinoma of the urinary bladder. Eur Urol 2002; 41 (3): 342–5.
33. Fernandez E, Gallus S, Bosetti C et al. Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer 2003; 105 (3): 408–12.
34. Godoy G, Gakis G, Smith CL, Fahmy O. Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression. Bladder Cancer 2016; 2 (2): 127–37.
35. Dellagrammaticas D, Bryden AA, Collins GN. Regression of metastatic transitional cell carcinoma in response to tamoxifen. J Urol 2001; 165 (5): 1631.
36. Shang Z, Li Y, Hsu I et al. Targeting estrogen/estrogen receptor alpha enhances Bacillus Calmette-Guérin efficacy in bladder cancer. Oncotarget 2016; 7 (19): 27325–35.
37. Tang B, Lv J, Li Y et al. Relationship between female hormonal and menstrual factors and pancreatic cancer: a meta-analysis of observational studies. Medicine (Baltimore) 2015; 94 (7): e177.
38. Kincade PW, Medina KL, Payne KJ et al. Early B-lymphocyte precursors and their regulation by sex steroid. Immunol Rev 2000; 175: 128–37.
39. Kauss MA, Reiterer G, Bunaciu RP, Yen A. Human myeloblastic leukemiacells (HL-60) express a membrane receptor for estrogen that signals and modulates retinoic acid-induced cell differentiation. Exp Cell Res 2008; 314 (16): 2999–3006.
40. Li Q, Kopecky KJ, Mohan A et al. Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia. Clin Cancer Res 1999; 5 (5): 1077–84.
41. Tavani A, Pregnolato A, La Vecchia C, Franceschi S. A case-control study of reproductive factors and risk of lymphomas and myelomas. Leuk Res 1997; 21 (9): 885–8.
42. Nelson RA, Levine AM, Bernstein L. Reproductive factors and risk of intermediate-or high-grade B-cell non-Hodgkin’s lymphoma in women.
J Clin Oncol 2001; 19 (5): 1381–7.
43. Medina KL, Strasser A, Kincade PW. Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors. Blood 2000; 95 (6): 2059–67.
44. Yang X, Wang C, He X et al. Hormone therapy for premature ovarian insufficiency patients with malignant hematologic diseases. Climacteric 2017; 20 (3): 268–73.
45. Tauchmanovà L, Selleri C, De Rosa G et al. Estrogen-progestin therapy in women after stem cell transplant: our experience and literature review. Menopause 2007; 14 (2): 320–30.
2. Hsu LH, Chu NM, Kao SH. Estrogen, Estrogen Receptor and Lung Cancer. Int J Mol Sci 2017; 18 (8): 1713.
3. Chlebowski RT, Anderson GL, Manson JE et al. Lung cancer among postmenopausal women treated with estrogen alone in the women’s health initiative randomized trial. J Natl Cancer Inst 2010; 102 (18): 1413–21.
4. Clague J, Reynolds P, Henderson KD et al. Menopausal hormone therapy and lung cancer-specific mortality following diagnosis: the California teachers study. PLoS One 2014; 9 (7): e103735.
5. Ganti AK, Sahmoun AE, Panwalkar AW et al. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 2016; 24 (1): 59–63.
6. Hammar M, Christau S, Nathorst-Boos J et al. A double-blind randomized trial comparing the effects of tibolone and continuous combined HRT in postmenopausal women with menopausal symptoms. Br J Obstet Gynecol 1998; 105: 904–11.
7. Vini L, Hyer S, Pratt B, Harmer C. Management of differentiated thyroid cancer diagnosed during pregnancy. Eur J Endocrinol 1999; 140: 404–6.
8. Moleti M, Sturniolo G, Di Mauro M et al. Female Reproductive Factors and Differentiated Thyroid Cancer. Front Endocrinol (Lausanne) 2017; 8: 111.
9. Truong T, Orsi L, Dubourdieu D et al. Role of goiter and of menstrual and reproductive factors in thyroid cancer: a population- based case-control study in New Caledonia (South Pacific), a very high incidence area. Am J Epidemiol 2005; 161 (11): 1056–65.
10. Sturniolo G, Zafon C, Moleti M et al. Immunohistochemical Expression of Estrogen Receptor-a and Progesterone Receptor in Patients with Papillary Thyroid Cancer. Eur Thyroid J 2016; 5 (4): 224–30.
11. Yi JW, Kim SJ, Kim JK et al. Upregulation of the ESR1 Gene and ESR Ratio (ESR1/ESR2) is Associated with a Worse Prognosis in Papillary Thyroid Carcinoma: The Impact of the Estrogen Receptor a/b Expression on Clinical Outcomes in Papillary Thyroid Carcinoma Patients. Ann Surg Oncol 2017; 24 (12): 3754–62.
12. Zamora-Ros R, Rinaldi S, Biessy C et al. Reproductive and menstrual factors and risk of differentiated thyroid. carcinoma: the EPIC study. Int J Cancer 2015; 136: 1218–27. DOI: 10.1002/ijc.29067
13. Jastrzebska H, Gietka-Czernel M, Zgliczyński S. Hormonal replacement therapy in women after surgery for thyroid cancer treated with suppressive doses of L-thyroxine. Wiad Lek 2001; 54 (Suppl. 1): 383–8.
14. De Giorgi V, Gori A, Savarese I et al. Role of BMI and hormone therapy in melanoma risk: a case–control study. J Cancer Res Clin Oncol 2017; 143 (7): 1191–7.
15. Botteri E, Støer NC, Sakshaug S et al. Menopausal hormone therapy and risk of melanoma: Do estrogens and progestins have a different role? Int J Cancer 2017; 141 (9): 1763–70.
16. Marzagalli M, Marelli MM, Casati L et al. Estrogen Receptor b in Melanoma: From Molecular Insights to Potential Clinical Utility. Front Endocrinol (Lausanne) 2016; 7: 140.
17. Marzagalli M, Casati L, Moretti RM et al. Estrogen receptor beta agonists differentially affect the growth of human melanoma cell lines. PLoS One 2015; 10 (7): e0134396.
18. De Giorgi V, Gori A, Gandini S et al. Oestrogen receptor beta and melanoma: a comparative study. Br J Dermatol 2013; 168 (3): 513–9.
19. MacKie RM, Bray CA. Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma. Br J Cancer 2004; 90 (4): 770–2.
20. Black PM. Hormones, radiosurgery and virtual reality: new aspects of meningiomamanagement. Can J Neurol Sci 1997; 24 (4): 302–6.
21. Carroll RS, Brown M, Zhang J et al. Expression of a subset of steroid receptor cofactors is associated with progesterone receptor expression in meningiomas. Clin Cancer Res 2000; 6: 3570–5.
22. Hsu DW, Efird JT, Hedley-Whyte ET. Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 1997; 86 (1): 113–20.
23. Hilbig A, Barbosa-Coutinho LM. Meningiomas and hormonal receptors. Immunohistochemical study in typical and nontypical tumors. Arq Neuropsiquiatr 1998; 56 (2): 193–9.
24. O'Shea T, Crowley RK, Farrell M et al. Growth of a progesterone receptor-positive meningioma in a female patient with congenital adrenal hyperplasia. Endocrinol Diabetes Metab Case Rep 2016. pii: 16-0054.
25. Pines A. Hormon therapy and brain tumors. Climacteric 2011; 14 (2): 215–6.
26. Benson VS, Kirichek O, Beral V, Green J. Menopausal hormone therapy and central nervous system tumor risk: large UK prospective study and meta-analysis. Int J Cancer 2015; 136 (10): 2369–77.
27. Deli T, Orosz M, Jakab A. Hormone Replacement Therapy in Cancer Survivors – Review of the Literature. Pathol Oncol Res 2019. https:.doi.org/10.1007/s12253-018-00569-x
28. Christin-Maître S, Delemer B, Touraine P, Young J. Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy. Ann Endocrinol (Paris) 2007; 68 (2–3): 106–12.
29. Karami S, Daugherty SE, Schonfeld SJ et al. Reproductive factors and kidney cancer risk in 2 US cohort studies, 1993–2010. Am J Epidemiol 2013; 177 (12): 1368–77.
30. Zucchetto A, Talamini R, Dal Maso L et al. Reproductive, menstrual, and other hormone-related factors and risk of renal cell cancer. Int J Cancer 2008; 123 (9): 2213–6.
31. Molokwu JC, Prizment AE, Folsom AR. Reproductive characteristics and risk of kidney cancer: IowaWomen’s. Maturitas 2007; 58 (2): 156–63.
32. Basakci A, Kirkali Z, Tuzel E et al. Prognostic significance of estrogen receptor expression in superficial transitional cell carcinoma of the urinary bladder. Eur Urol 2002; 41 (3): 342–5.
33. Fernandez E, Gallus S, Bosetti C et al. Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer 2003; 105 (3): 408–12.
34. Godoy G, Gakis G, Smith CL, Fahmy O. Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression. Bladder Cancer 2016; 2 (2): 127–37.
35. Dellagrammaticas D, Bryden AA, Collins GN. Regression of metastatic transitional cell carcinoma in response to tamoxifen. J Urol 2001; 165 (5): 1631.
36. Shang Z, Li Y, Hsu I et al. Targeting estrogen/estrogen receptor alpha enhances Bacillus Calmette-Guérin efficacy in bladder cancer. Oncotarget 2016; 7 (19): 27325–35.
37. Tang B, Lv J, Li Y et al. Relationship between female hormonal and menstrual factors and pancreatic cancer: a meta-analysis of observational studies. Medicine (Baltimore) 2015; 94 (7): e177.
38. Kincade PW, Medina KL, Payne KJ et al. Early B-lymphocyte precursors and their regulation by sex steroid. Immunol Rev 2000; 175: 128–37.
39. Kauss MA, Reiterer G, Bunaciu RP, Yen A. Human myeloblastic leukemiacells (HL-60) express a membrane receptor for estrogen that signals and modulates retinoic acid-induced cell differentiation. Exp Cell Res 2008; 314 (16): 2999–3006.
40. Li Q, Kopecky KJ, Mohan A et al. Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia. Clin Cancer Res 1999; 5 (5): 1077–84.
41. Tavani A, Pregnolato A, La Vecchia C, Franceschi S. A case-control study of reproductive factors and risk of lymphomas and myelomas. Leuk Res 1997; 21 (9): 885–8.
42. Nelson RA, Levine AM, Bernstein L. Reproductive factors and risk of intermediate-or high-grade B-cell non-Hodgkin’s lymphoma in women.
J Clin Oncol 2001; 19 (5): 1381–7.
43. Medina KL, Strasser A, Kincade PW. Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors. Blood 2000; 95 (6): 2059–67.
44. Yang X, Wang C, He X et al. Hormone therapy for premature ovarian insufficiency patients with malignant hematologic diseases. Climacteric 2017; 20 (3): 268–73.
45. Tauchmanovà L, Selleri C, De Rosa G et al. Estrogen-progestin therapy in women after stem cell transplant: our experience and literature review. Menopause 2007; 14 (2): 320–30.
________________________________________________
1. Miki Y, Abe K, Suzuki S et al. Suppression of estrogen actions in human lung cancer. Mol Cell Endocrinol 2011; 340 (2): 168–74.
2. Hsu LH, Chu NM, Kao SH. Estrogen, Estrogen Receptor and Lung Cancer. Int J Mol Sci 2017; 18 (8): 1713.
3. Chlebowski RT, Anderson GL, Manson JE et al. Lung cancer among postmenopausal women treated with estrogen alone in the women’s health initiative randomized trial. J Natl Cancer Inst 2010; 102 (18): 1413–21.
4. Clague J, Reynolds P, Henderson KD et al. Menopausal hormone therapy and lung cancer-specific mortality following diagnosis: the California teachers study. PLoS One 2014; 9 (7): e103735.
5. Ganti AK, Sahmoun AE, Panwalkar AW et al. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 2016; 24 (1): 59–63.
6. Hammar M, Christau S, Nathorst-Boos J et al. A double-blind randomized trial comparing the effects of tibolone and continuous combined HRT in postmenopausal women with menopausal symptoms. Br J Obstet Gynecol 1998; 105: 904–11.
7. Vini L, Hyer S, Pratt B, Harmer C. Management of differentiated thyroid cancer diagnosed during pregnancy. Eur J Endocrinol 1999; 140: 404–6.
8. Moleti M, Sturniolo G, Di Mauro M et al. Female Reproductive Factors and Differentiated Thyroid Cancer. Front Endocrinol (Lausanne) 2017; 8: 111.
9. Truong T, Orsi L, Dubourdieu D et al. Role of goiter and of menstrual and reproductive factors in thyroid cancer: a population- based case-control study in New Caledonia (South Pacific), a very high incidence area. Am J Epidemiol 2005; 161 (11): 1056–65.
10. Sturniolo G, Zafon C, Moleti M et al. Immunohistochemical Expression of Estrogen Receptor-a and Progesterone Receptor in Patients with Papillary Thyroid Cancer. Eur Thyroid J 2016; 5 (4): 224–30.
11. Yi JW, Kim SJ, Kim JK et al. Upregulation of the ESR1 Gene and ESR Ratio (ESR1/ESR2) is Associated with a Worse Prognosis in Papillary Thyroid Carcinoma: The Impact of the Estrogen Receptor a/b Expression on Clinical Outcomes in Papillary Thyroid Carcinoma Patients. Ann Surg Oncol 2017; 24 (12): 3754–62.
12. Zamora-Ros R, Rinaldi S, Biessy C et al. Reproductive and menstrual factors and risk of differentiated thyroid. carcinoma: the EPIC study. Int J Cancer 2015; 136: 1218–27. DOI: 10.1002/ijc.29067
13. Jastrzebska H, Gietka-Czernel M, Zgliczyński S. Hormonal replacement therapy in women after surgery for thyroid cancer treated with suppressive doses of L-thyroxine. Wiad Lek 2001; 54 (Suppl. 1): 383–8.
14. De Giorgi V, Gori A, Savarese I et al. Role of BMI and hormone therapy in melanoma risk: a case–control study. J Cancer Res Clin Oncol 2017; 143 (7): 1191–7.
15. Botteri E, Støer NC, Sakshaug S et al. Menopausal hormone therapy and risk of melanoma: Do estrogens and progestins have a different role? Int J Cancer 2017; 141 (9): 1763–70.
16. Marzagalli M, Marelli MM, Casati L et al. Estrogen Receptor b in Melanoma: From Molecular Insights to Potential Clinical Utility. Front Endocrinol (Lausanne) 2016; 7: 140.
17. Marzagalli M, Casati L, Moretti RM et al. Estrogen receptor beta agonists differentially affect the growth of human melanoma cell lines. PLoS One 2015; 10 (7): e0134396.
18. De Giorgi V, Gori A, Gandini S et al. Oestrogen receptor beta and melanoma: a comparative study. Br J Dermatol 2013; 168 (3): 513–9.
19. MacKie RM, Bray CA. Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma. Br J Cancer 2004; 90 (4): 770–2.
20. Black PM. Hormones, radiosurgery and virtual reality: new aspects of meningiomamanagement. Can J Neurol Sci 1997; 24 (4): 302–6.
21. Carroll RS, Brown M, Zhang J et al. Expression of a subset of steroid receptor cofactors is associated with progesterone receptor expression in meningiomas. Clin Cancer Res 2000; 6: 3570–5.
22. Hsu DW, Efird JT, Hedley-Whyte ET. Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 1997; 86 (1): 113–20.
23. Hilbig A, Barbosa-Coutinho LM. Meningiomas and hormonal receptors. Immunohistochemical study in typical and nontypical tumors. Arq Neuropsiquiatr 1998; 56 (2): 193–9.
24. O'Shea T, Crowley RK, Farrell M et al. Growth of a progesterone receptor-positive meningioma in a female patient with congenital adrenal hyperplasia. Endocrinol Diabetes Metab Case Rep 2016. pii: 16-0054.
25. Pines A. Hormon therapy and brain tumors. Climacteric 2011; 14 (2): 215–6.
26. Benson VS, Kirichek O, Beral V, Green J. Menopausal hormone therapy and central nervous system tumor risk: large UK prospective study and meta-analysis. Int J Cancer 2015; 136 (10): 2369–77.
27. Deli T, Orosz M, Jakab A. Hormone Replacement Therapy in Cancer Survivors – Review of the Literature. Pathol Oncol Res 2019. https:.doi.org/10.1007/s12253-018-00569-x
28. Christin-Maître S, Delemer B, Touraine P, Young J. Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy. Ann Endocrinol (Paris) 2007; 68 (2–3): 106–12.
29. Karami S, Daugherty SE, Schonfeld SJ et al. Reproductive factors and kidney cancer risk in 2 US cohort studies, 1993–2010. Am J Epidemiol 2013; 177 (12): 1368–77.
30. Zucchetto A, Talamini R, Dal Maso L et al. Reproductive, menstrual, and other hormone-related factors and risk of renal cell cancer. Int J Cancer 2008; 123 (9): 2213–6.
31. Molokwu JC, Prizment AE, Folsom AR. Reproductive characteristics and risk of kidney cancer: IowaWomen’s. Maturitas 2007; 58 (2): 156–63.
32. Basakci A, Kirkali Z, Tuzel E et al. Prognostic significance of estrogen receptor expression in superficial transitional cell carcinoma of the urinary bladder. Eur Urol 2002; 41 (3): 342–5.
33. Fernandez E, Gallus S, Bosetti C et al. Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer 2003; 105 (3): 408–12.
34. Godoy G, Gakis G, Smith CL, Fahmy O. Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression. Bladder Cancer 2016; 2 (2): 127–37.
35. Dellagrammaticas D, Bryden AA, Collins GN. Regression of metastatic transitional cell carcinoma in response to tamoxifen. J Urol 2001; 165 (5): 1631.
36. Shang Z, Li Y, Hsu I et al. Targeting estrogen/estrogen receptor alpha enhances Bacillus Calmette-Guérin efficacy in bladder cancer. Oncotarget 2016; 7 (19): 27325–35.
37. Tang B, Lv J, Li Y et al. Relationship between female hormonal and menstrual factors and pancreatic cancer: a meta-analysis of observational studies. Medicine (Baltimore) 2015; 94 (7): e177.
38. Kincade PW, Medina KL, Payne KJ et al. Early B-lymphocyte precursors and their regulation by sex steroid. Immunol Rev 2000; 175: 128–37.
39. Kauss MA, Reiterer G, Bunaciu RP, Yen A. Human myeloblastic leukemiacells (HL-60) express a membrane receptor for estrogen that signals and modulates retinoic acid-induced cell differentiation. Exp Cell Res 2008; 314 (16): 2999–3006.
40. Li Q, Kopecky KJ, Mohan A et al. Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia. Clin Cancer Res 1999; 5 (5): 1077–84.
41. Tavani A, Pregnolato A, La Vecchia C, Franceschi S. A case-control study of reproductive factors and risk of lymphomas and myelomas. Leuk Res 1997; 21 (9): 885–8.
42. Nelson RA, Levine AM, Bernstein L. Reproductive factors and risk of intermediate-or high-grade B-cell non-Hodgkin’s lymphoma in women.
J Clin Oncol 2001; 19 (5): 1381–7.
43. Medina KL, Strasser A, Kincade PW. Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors. Blood 2000; 95 (6): 2059–67.
44. Yang X, Wang C, He X et al. Hormone therapy for premature ovarian insufficiency patients with malignant hematologic diseases. Climacteric 2017; 20 (3): 268–73.
45. Tauchmanovà L, Selleri C, De Rosa G et al. Estrogen-progestin therapy in women after stem cell transplant: our experience and literature review. Menopause 2007; 14 (2): 320–30.
Авторы
О.В.Якушевская*1, С.В.Юренева1, А.Э.Протасова2–5, Г.Н.Хабас1, Л.А.Ашрафян1
1. ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова» Минздрава России. 117997, Россия, Москва, ул. Академика Опарина, д. 4;
2. ФГБОУ ВО «Санкт-Петербургский государственный университет». 199034, Россия, Санкт-Петербург, Университетская наб. д. 7/9;
3. ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И.Мечникова» Минздрава России. 191015, Россия, Санкт-Петербург, ул. Кирочная, д. 41;
4. ФГБУ «Северо-Западный федеральный медицинский исследовательский центр им. В.А.Алмазова» Минздрава России. 197341, Россия, Санкт-Петербург, ул. Аккуратова, д. 2;
5. ООО «АВА-ПЕТЕР». 191186, Россия, Санкт-Петербург, Невский пр-т, д. 22-24
*aluckyone777@gmail.com
1. ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова» Минздрава России. 117997, Россия, Москва, ул. Академика Опарина, д. 4;
2. ФГБОУ ВО «Санкт-Петербургский государственный университет». 199034, Россия, Санкт-Петербург, Университетская наб. д. 7/9;
3. ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И.Мечникова» Минздрава России. 191015, Россия, Санкт-Петербург, ул. Кирочная, д. 41;
4. ФГБУ «Северо-Западный федеральный медицинский исследовательский центр им. В.А.Алмазова» Минздрава России. 197341, Россия, Санкт-Петербург, ул. Аккуратова, д. 2;
5. ООО «АВА-ПЕТЕР». 191186, Россия, Санкт-Петербург, Невский пр-т, д. 22-24
*aluckyone777@gmail.com
________________________________________________
Oksana V. Iakushevskaia*1, Svetlana V. Iureneva1, Anna E. Protasova2–5, Grigorii N. Khabas1, Lev A. Ashrafian1
1. V.I.Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health
of the Russian Federation. 4, Akademika Oparina st., Moscow, 117997, Russian Federation;
2. Saint Petersburg State University. 7/9, Universitetskaia nab., Saint Petersburg, 199034, Russian Federation;
3. I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation. 41, Kirochnaia st., Saint Petersburg, 191015, Russian Federation;
4. V.A.Almazov North-West Federal Medical Research Center of the Ministry of Health of the Russian Federation. 2, Akkuratova st., Saint Petersburg, 197341, Russian Federation;
5. AVA-PETER. 22-24, Nevsky av., Saint Petersburg, 191186, Russian Federation
*aluckyone777@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.